SCHEMBL5688602

SCHEMBL5688602

Cc1ccc(Cc2ccc(OC(=O)N3CCC(Sc4nnnn4CCN(C)C)CC3)cc2)nc1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 3/20 0.34
UBE2M P61081 4/20 0.33
DCUN1D1 Q96GG9 4/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
P2RX3 P56373 1/20 0.32
PIK3CD O00329 1/20 0.32
BCHE P06276 4/20 0.32
CNR2 P34972 3/20 0.32
SMO Q99835 1/20 0.31
ACHE P22303 1/20 0.31
TLR9 Q9NR96 1/20 0.31
TLR8 Q9NR97 1/20 0.31
TLR7 Q9NYK1 1/20 0.31
LIPE Q05469 1/20 0.31
KEAP1 Q14145 1/20 0.31
NFE2L2 Q16236 1/20 0.31
TRPV1 Q8NER1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5688142 0.93 AOC3 (0.35) GRIN2BUBE2MDCUN1D1CYP1A2CYP2C9
SCHEMBL5688370 0.91 SMO (0.33) CYP1A2CYP2C9CYP2C19P2RX3PIK3CD
SCHEMBL5688346 0.89 LIPE (0.44) UBE2MDCUN1D1BCHELIPE
SCHEMBL5688785 0.89 NPY2R (0.35) CYP1A2CYP2C9CYP2C19P2RX3BCHE
SCHEMBL5690077 0.89 ALDH1A1 (0.35) CYP1A2CYP2C9CYP2C19P2RX3BCHE
SCHEMBL5688888 0.88 NOS3 (0.34) GRIN2BUBE2MDCUN1D1P2RX3BCHE
SCHEMBL5687424 0.88 GAA (0.35) GRIN2BUBE2MDCUN1D1SMOTRPV1
SCHEMBL5687632 0.86 UBE2M (0.36) UBE2MDCUN1D1CYP1A2CYP2C19SMO
SCHEMBL5687968 0.84 AOC3 (0.35) CYP1A2CYP2C9CYP2C19P2RX3PIK3CD
SCHEMBL5690242 0.84 SMO (0.36) GRIN2BUBE2MDCUN1D1SMOTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC GRIN2B 2588/4885UBE2M 3021/4885DCUN1D1 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.